TapImmune announced that the Food & Drug Administration (FDA) has granted Fast Track designation for its cancer vaccine TPIV 200 in the treatment of ovarian cancer.
TPIV 200 cancer vaccine is under investigation as a maintenance therapy with GM-CSF adjuvant in patients with platinum-sensitive advanced ovarian cancer, who achieved stable disease or partial response following completion of standard of care chemotherapy.
The FDA recently granted TPIV 200 Orphan Drug designation for the same indication in December 2015.
TPIV 200 is a multiple-epitope folate receptor alpha peptide vaccine.
For more information visit TapImmune.com.